Related Experiment Video
Updated: Aug 15, 2025
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors
Homma M Khosroyani1, Lillian R Klug1, Michael C Heinrich2
1Portland VA Health Care System and Knight Cancer Institute, Oregon Health & Science University, R&D-19, 3710 SW US Veterans Hospital Road, Portland, OR, 97239, USA.
Abstract:
Prior to the early 2000s, patients with advanced gastrointestinal stromal tumors (GIST) had very poor prognoses owing to a lack of effective therapies. The development of tyrosine kinase inhibitors at the turn of the century significantly improved the overall survival for patients with GIST. The resounding success of imatinib in the first clinical trial of a tyrosine kinase inhibitor to treat GIST led to its approval for first-line therapy for advanced GIST; this study was open to all comers and not restricted to any GIST subtype(s). The trials that led to the approvals of second-, third-, and fourth-line therapy for advanced GIST were also open to all patients with advanced/metastatic GIST. Only in retrospect do we realize the role that the molecular subtypes played in the results observed in these studies. In this review, we discuss the studies that led to the US Food and Drug Administration approval of imatinib (first line), sunitinib (second line), regorafenib (third line), and ripretinib (fourth line) for advanced KIT-mutant GIST. In addition, we review how information about GIST molecular subtypes has been used to accelerate the approval of other targeted therapies for non-KIT mutant GIST, leading to the approval of five additional drugs indicated for the treatment of specific GIST molecular subtypes. We also discuss how our understanding of the molecular subtypes will play a role in the next generation of therapeutic approaches for treating advanced GIST.
Insights
Tyrosine kinase inhibitors have transformed advanced gastrointestinal stromal tumors (GIST) treatment. Understanding GIST molecular subtypes is crucial for developing targeted therapies and improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Advanced gastrointestinal stromal tumors (GIST) historically had poor prognoses due to limited treatment options.
- The advent of tyrosine kinase inhibitors (TKIs) in the early 2000s revolutionized GIST management, significantly improving patient survival.
- Early TKI trials for GIST were open to all patients, without initial consideration for specific molecular subtypes.
Purpose of the Study:
- To review the clinical trials leading to the FDA approval of first- through fourth-line TKIs for advanced KIT-mutant GIST.
- To examine how molecular subtype information has accelerated the development of targeted therapies for non-KIT mutant GIST.
- To discuss the future role of molecular subtyping in advancing GIST treatment strategies.
Main Methods:
- Review of pivotal clinical trials for imatinib, sunitinib, regorafenib, and ripretinib in advanced GIST.
- Analysis of the impact of GIST molecular subtyping on drug development and approval processes.
- Synthesis of current understanding and future directions in targeted GIST therapy.
Main Results:
- Imatinib, sunitinib, regorafenib, and ripretinib are approved for advanced KIT-mutant GIST, based on landmark trials.
- Knowledge of GIST molecular subtypes has enabled the approval of five additional targeted therapies for specific subtypes.
- Personalized medicine approaches based on molecular profiling are becoming standard in advanced GIST care.
Conclusions:
- Targeted therapies, guided by molecular subtyping, have dramatically improved outcomes for advanced GIST patients.
- Continued research into GIST molecular heterogeneity will drive the development of next-generation therapies.
- Precision medicine is essential for optimizing treatment and improving survival in advanced GIST.
